Skip to search formSkip to main contentSkip to account menu

Reyataz

National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

AtazanavirAtazanavir sulfate
Atazanavir 50 MG Oral Powder [Reyataz]Atazanavir Oral Capsule [Reyataz]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Cost del tractament del SIDA i d'Hepatitis C per a l'Estat : Comparació de la despesa d'una persona en llibertat vs. un pres
Un dels principals motius que ens va impulsar en l’eleccio del tema es que es tracta d’untema que pot despertar curiositat entre… 
2009
2009
Market watch: Sales from licensed and acquired products to increase by 2013
AVos Life sciences has analysed the revenue contribution of organically developed, licensed or co-developed, acquired and joint… 
2005
2005
Boosted Reyataz comparable to Kaletra.
2004
2004
Warning: do not combine Reyataz and Prilosec.
The combination has been found to reduce blood levels of the antiretroviral to about a quarter of what they should be. 
2004
2004
Boosted Reyataz: 48-week results.
2003
2003
Atazanavir (Reyataz).
Atazanavir (Reyataz) is a protease inhibitor that received FDA approval in June 2003. Other approved drugs in this class include… 
2003
2003
FDA notifications. Reyataz is approved for HIV treatment.
Reyataz, protease inhibitor, is to be used in combination with other antiretroviral agents for the treatment of patients with HIV… 
2003
2003
Drug profile: atazanavir (Reyataz, ATV).
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)